About UBS Group AG Registered Ordinary Shares (UBS)
UBS Group AG is a global financial services company providing a wide range of financial services to clients, including wealth management, investment banking, and asset management. The firm caters to private, corporate, and institutional clients, delivering tailored financial solutions and expertise across various sectors and regions. UBS is known for its strong focus on sustainable finance and innovation, striving to create long-term value for its stakeholders while maintaining a commitment to corporate responsibility and ethical practices in the financial industry. Read More
UBS Global Wealth Management US today announced that J. Mills-Pierre III has joined the firm as a Financial Advisor. Mills joins the UBS Manhattan Market, led by Market Executive Kellie Brady, and is based in the firm’s 299 Park Avenue location. He reports to Market Director Neal Cooper and Associate Market Executive Demie Kommatas.
Shares of healthcare insurance company Molina Healthcare (NYSE:MOH)
fell 3.8% in the afternoon session after TD Cowen lowered its price target on the stock to $283 from $369, citing elevated medical costs.
Shares of online marketplace Etsy (NASDAQ:ETSY)
jumped 3.1% in the pre-market session after the company received positive attention from Wall Street analysts, including an upgrade from Morgan Stanley and a price target increase from UBS.
With over three decades of experience in financial advising, Clark Smith of Golden Years Financial remains a trusted leader in the retirement planning space. From his early days as the youngest Retirement Planning Specialist at Dean Witter Reynolds to managing a small hedge fund at Woodridge Partners, Smith has built a career on empowering clients to retire with confidence and clarity.
With over three decades of experience in financial advising, Clark Smith of Golden Years Financial remains a trusted leader in the retirement planning space. From his early days as the youngest Retirement Planning Specialist at Dean Witter Reynolds to managing a small hedge fund at Woodridge Partners, Smith has built a career on empowering clients […]
Shares of health insurance company Oscar Health (NYSE:OSCR) fell 3.1% in the morning session after the stock continued a sharp decline from the previous session, which was fueled by multiple analyst downgrades and broader weakness in the healthcare plans sector.
UBS Global Wealth Management US announced that Christopher Brolly has joined the firm as a Financial Advisor. He joins the UBS Greater New England Market, led by Market Executive James Ducey, and will report to Boston Wealth Management Senior Market Director Robert Covino.
UBS Global Wealth Management US today announced the appointment of Kathleen (Kathy) Ferraro, a seasoned executive with over three decades of experience, as the new Market Director for its Greenwich and Stamford, Connecticut offices. In this role, Kathy will be responsible for leading advisor development, elevating the client experience and advancing strategic growth across these key markets.
The food and beverage giant has been under pressure for several quarters, weighed down by shifting consumer preferences toward healthier options, stiff competition, and broader weakness in consumer spending.
UBS Global Wealth Management US today announced that Jack Heiss will join the firm as Market Director for its Tampa, Clearwater, St. Petersburg, Sarasota, and Winter Haven offices in Florida. He will begin his role at the conclusion of his notice period.
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY)
fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other headwinds. Ahead of its second-quarter earnings report, UBS reiterated its "Neutral" rating on the stock. The firm's note pointed to several challenges, including an expected $1.5 billion expense for in-process research and development (IPR&D) related to a collaboration with BioNTech. This charge is anticipated to reduce the company's earnings per share (EPS) by approximately $0.60. The report also touched on broader investor concerns, such as the impact of Medicare's Part D redesign on several of the company's high-priced drugs and the looming patent expirations for key products. These factors contribute to a more cautious outlook on the pharmaceutical giant's near-term profitability and growth prospects.
Many investors have soured on this former market darling, but that may be a "go" sign for new buyers in light of its quiet and underappreciated progress on the AI front.
